Heather, Jesus, and Toya, actual patients
PROLASTIN-C LIQUID patient stories
Meet 3 patients receiving PROLASTIN-C LIQUID and see how PROLASTIN-C LIQUID has made a difference in their lives. Hear what Heather, Jesus, and Toya have to say about alpha-1 and their experience with PROLASTIN-C LIQUID in their videos.
My PROLASTIN-C LIQUID means a treatment that fits my life.
“I want to make sure I am in control of alpha-1, and alpha-1 is not in control of me.”
—Heather, actual patient since 2018
My PROLASTIN-C LIQUID means one simple infusion, once a week.
“PROLASTIN-C LIQUID is easy to work into your routine. I receive my infusions at home.”
—Jesus, actual patient since 2016
My PROLASTIN-C LIQUID means feeling real support.
“With PROLASTIN-C LIQUID, we gain a community that is incredibly unique.”
—Toya, actual patient since 2016
Ready to talk with your doctor about treating your alpha-1?
Be prepared with a free PROLASTIN-C LIQUID doctor discussion guide.
Important Safety Information
PROLASTIN®-C LIQUID is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).
Limitations of Use
- The effect of augmentation therapy with any alpha1-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha1-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials
- Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available
- PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established
PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha1-PI products.
Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.
Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.
The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).
Please see full Prescribing Information for PROLASTIN-C LIQUID.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.